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Abstract
Endotoxin producing bacteria cause disseminated intravascular
coagulation (DIC); however, the mechanism of endotoxin action
in man is still unclear. Impairment of the fibrinolytic system
has been suggested as a contributing mechanism.
A single injection of Escherichia coli lipopojysaccharide in
rabbits resulted in a marked and prolonged increase of the
levels of a fast-acting inhibitor of plasminogen activator (PA-
inhibitor) in plasma (from 3.9±0.7 to 41±13.2 U/ml after 3
h). Gel filtration studies indicated that inhibition of human
tissue-type plasminogen activator (t-PA) by rabbit plasma is
accompanied by a change in the elution profile of the activator
compatible with the formation of an enzyme-inhibitor complex
with an apparent molecular weight of 100,000. Injection of
human t-PA (1,500 IU/kg body wt) in endotoxin treated
animals resulted in very fast inhibition of t-PA and formation
of a similar complex.
The half-life of circulating PA-inhibitor activity in rabbits
was about 7 min as estimated by donor receiver plasma
transfusion experiments.
Stimulation of cultured human endothelial cells with en-
dotoxin resulted in enhanced rate of accumulation of PA-
inhibitor activity in the culture medium (two- to sevenfold
increase). In five patients with septicemia, markedly increased
levels of PA-inhibitor (14.3±15.5 U/ml) as compared with
control subjects (13±0.7 U/ml) were observed in plasma.
A very strong correlation (r = 0.98) was found between
inhibition of t-PA and of urokinase in all conditions, suggesting
that this fast-acting inhibitor reacts with both plasminogen
activators.
These data suggest that the appearance of this fast-acting
PA-inhibitor is very sensitive to endotoxin stimulation. The
marked increase in the level of PA-inhibitor in blood may
contribute to the pathogenesis of DIC in septicemia.
Introduction
Bacterial infections may cause disseminated intravascular co-
agulation (DIC)' and fibrin deposition in the microcirculation
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(1, 2). Endotoxin, a cell wall constituent of gram-negative
bacteria, has been shown to be the main trigger of these
phenomena (3). Its mechanism of action, however, is not
completely clarified.
Endotoxin-induced DIC is a multifactorial process that
involves both cellular and humoral pathways (3). Endothelial
cell damage with exposure of the subendothelial structures has
been proposed as one of the main pathogenetic mechanisms
(3, 4). In addition, endotoxin-stimulated endothelial cells may
trigger blood coagulation by producing procoagulant (throm-
boplastin-like) activity (5).
Deficient fibrinolysis may contribute to the precipitation
of fibrin within blood vessels (6). Indeed, the fibrinolytic
system plays a role not only in the removal of formed fibrin
but also in the prevention of fibrin deposition (7).
Endothelial cells produce and release plasminogen activa-
tor(s) and inhibitor(s) of plasminogen activation (8-12). Recent
reports have shown that circulating blood contains a fast-
acting inhibitor of tissue-type plasminogen activator (t-PA)
and urokinase (UK) (PA-inhibitor) (13-15) that may be iden-
tical to the inhibitor produced by endothelial cells.
This study shows that (a) injection of very small amounts
of endotoxin in rabbits induces a marked increase of PA-
inhibitor activity in circulating blood, (b) endotoxin enhances
the accumulation of PA-inhibitor activity in the culture medium
of human endothelial cells, and (c) patients with septicemia
have markedly increased levels of PA-inhibitor in blood.
It is concluded that the appearance of PA-inhibitor activity
after endotoxin stimulation may play a significant role in the
pathogenesis of DIC associated with septicemia. Endotoxin
stimulation, in experimental animals, may provide a useful
model for the investigation of the biological role of PA-
inhibitor.
Methods
Materials. Human melanoma cell t-PA, human plasminogen, and
human fibrinogen were purified by published methods (16-18). Uro-
kinase (UK) (Winkinase) was a gift from Dr. G. Murano, Bureau of
Biologics, Food and Drug Administration, Bethesda, MD. Fibrinogen
was digested with CNBr as previously described (19). Fibrinogen was
labeled with 1251 using the Iodo-Gen procedure (20), t-PA was immo-
bilized by coupling to CNBr-activated Sepharose 4B (0.2 mg protein/
g gel). Escherichia coli 011 :B4 lipopolysaccharide (LPS) W was
purchased from Difco Laboratories, Inc., Detroit, MI. The synthetic
substrate D-Val-Leu-Lys-pNA (S-225 1) was purchased from Kabi Diag-
nostica, Stockholm, Sweden. Arg-vasopressin (AVP) was purchased
from Sigma Chemical Co., St. Louis, MO. D-Ile-Pro-Arg-CH2CI, a
synthetic inhibitor of t-PA, is characterized elsewhere (21).
1. Abbreviations used in this paper: AVP, Arg-vasopressin; DIC,
disseminated intravascular coagulation; HEC, human endothelial cells;
LPS, lipopolysaccharide; PA-inhibitor, designation used for a fast-
acting inhibitor of tissue-type plasminogen activator and urokinase;
t-PA, tissue-type plasminogen activator; UK, urokinase.
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In vivo experiments. New Zealand rabbits, weighing 1.8-2.1 kg,
were anesthetized by intramuscular injection of 0.4 ml/kg body wt of
Hypnorm (Duphar, Amsterdam, The Netherlands) containing 10 mg/
ml fluanisone and 0.2 mg/ml fentanil. Additional Hypnorm (0.3 ml
every 2 h) was administered to maintain anesthesia. LPS injections
were given via a marginal ear vein. Blood samples (2 ml) were taken
through a catheter inserted into a femoral vein and anticoagulated
with 4% trisodium citrate (9 vol of blood plus 1 vol of anticoagulant)
or, when specified, with citrate plus D-Ile-Pro-Arg-CH2Cl (2 X l0-4 M
final concentration). Samples were immediately chilled in melting ice;
plasma was isolated by short centrifugation (2 min at 12,000 g) within
10 min of sampling and kept on ice until tested.
In vitro studies. Human endothelial cells (HEC) were prepared
from umbilical cord veins as described (10). The endothelial cells were
aliquoted in tissue culture plates with flat-bottomed wells of 16 mm
diam (Becton-Dickinson & Co., Oxnard, CA). After 7-8 d, primary
confluent cultures containing only the typical cobblestone patterns of
endothelial cells were used. The average number of cells was 2 X 10'
per well. Each series of experiments was performed on cultures derived
from the same umbilical cord vein. The culture medium was removed,
the cell monolayers were washed three times with serum-free medium,
and then 0.8 ml of fresh culture medium containing 5% of heat-
inactivated human serum (30 min at 560C) was added. E. coli LPS or
sterile saline were added to the cells and the cultures were incubated
at 370C. Aliquots of conditioned culture medium were taken at the
indicated time intervals to assay PA-inhibitor activity. The cell associated
PA-inhibitor activity was evaluated as follows. After 12-14 h incubation
with endotoxin or saline, the culture medium was removed and the
cell monolayers were washed three times with phosphate-buffered
saline (PBS). Cells were then extracted with 0.5% Triton X-100 (0.2
ml) for 30 min at room temperature. Alternatively, the endothelial
cells were disrupted by freezing and thawing (5) and were centrifuged
15 min at 40,000 g. The supernatant (soluble fraction) was collected
and the pellet (membrane fraction) was washed twice with PBS and
then extracted with Triton X-100.
Blood platelets and leukocytes were isolated as described elsewhere
(22, 23). Final suspensions were in PBS and contained 5 X 105 platelets/
,u and 104 leucocytes/ul, respectively. Cells were extracted with Triton
X-100 as outlined above.
Assay ofplasminogen activator activity. Fibrinolytic activity of the
euglobulin fraction of rabbit plasma was evaluated by measuring the
release of 125I from radiolabeled fibrin films (24, 25). 100 Ml of
euglobulins was added to the wells and the plates were incubated at
37°C. 10-Ml samples were removed at fixed time intervals for the
measurement of '12I-fibrin split products. Plasminogen activator activity
was expressed in international units (16) by reference to a standard
curve made with purified human t-PA in plasminogen-containing
(0.25-MM) wells.
t-PA activity in plasma after injection ofhuman t-PA was measured
with the fibrin plate method (26) as reported (16), and with a synthetic
substrate assay (27). In the latter case, citrated blood samples (0.4 ml)
were immediately acidified with 1 M Na-acetate, pH 3.9 (0.2 ml), and
centrifuged. The resulting plasma was incubated for an additional 10
min at room temperature and then diluted 1/50 in 0.02 M Tris HCl,
0.1 M NaCI, 0.01% Triton X-100, pH 8.8. The samples were kept on
ice until tested for t-PA activity. 100 Ml of the test solution and 100 M1
of a mixture containing 0.25 MM human plasminogen, 0.6 mM
S-225 1, and 0.09 g/l CNBr fibrinogen digest were added in a microtiter
plate. The plate was incubated at 37°C and the change in absorbance
at 405 nm was measured with a titertek multiskan spectrophotometer
(Flow Laboratories, Inc., McLean, VA).
t-PA related antigen was measured using a two-site immunoradio-
metric assay as previously described (28).
Assay of PA-inhibitor activity. Samples were diluted 1/4 or more
in 0.02 M Tris-HC1, 0.1 M NaCl, 0.01% Triton X-100, pH 8.8 (Tris
buffer), and incubated for 1 min at 37°C in the presence of t-PA or
UK (2 IU/ml final concentration). The samples (100 Ml) were then
acidified with 100 gl of 0.16 M HCO and incubated 10 min at room
temperature. This procedure resulted in complete neutralization of the
plasmin inhibitor activity in plasma. The pH was then adjusted by the
addition of 100 Ml of 0.16 M NaOH and 700 M1 of Tris buffer. The
residual plasminogen activator activity was measured by the synthetic
substrate assay described above. Inhibitor activity was expressed in
units of plasminogen activator inhibited per milliliter.
Fibrin polymerization time, activated partial thromboplastin time,
and platelet count were performed by standard laboratory assays.
Gel filtration of plasma samples (0.5 ml) was performed on an
Ultrogel AcA 44 column (30 X 1.6 cm) equilibrated with 0.02 M
Tris HC1, 0.3 M NaCl, 0.01 M trisodium citrate, and 0.02% Tween
80, pH 7.4. The flow rate was 10 ml/h and fractions of I ml were
collected. Relative molecular weight markers were: human IgGs, Mr
= 150,000; phosphorylase b, M, = 98,000; and human albumin, Mr
= 66,000.
Adsorption of PA-inhibitor activity from samples was carried out
as follows. t-PA-Sepharose was added to the sample (100 mg gel/ml)
and the mixture was incubated at 370C for 30 min under continuous
mixing. The gel was sedimented by centrifugation (2 min at 12,000 g)
and the top fraction of the supernatant was collected.
Patients. The PA-inhibitor activity of plasma was studied in five
patients with septicemia; four males and one female, aged 22-76 yr
(mean 57). Bacteriological studies identified E. coli, Pseudomona
aeruginosa, and Streptococcus viridans. A control group consisted
of 50 healthy subjects, 31 males and 19 females, aged 26-61 yr
(mean 39).
Results
In vivo studies in rabbits. The PA-inhibitor activity in the
plasma of rabbits after injection of E. coli LPS is illustrated in
Fig. 1 A. After 3 h of endotoxin administration, the inhibitor
levels rose from 3.9±0.7 U/ml to 41±13.2 U/ml. This level
was maintained for an additional 5 h and had returned to the
preinjection value after 24 h. Adsorption of plasma obtained
from endotoxin treated animals with t-PA-Sepharose completely
removed the PA-inhibitor activity (not shown).
With this endotoxin preparation, overt signs of intravascular
coagulation, such as drop in platelet count, reduction of
fibrinogen levels, and prolongation of the activated partial
thromboplastin time, were visible only when a dose of 200
Mg/kg body wt was given to the animals, whereas a PA-
inhibitor response (more than fivefold increase) was clearly
observed with a dose as low as 10 ng/kg (Fig. 1 B).
PA-inhibitor activity was barely detectable in extracts of
washed blood platelets and leukocytes (0.14±0.2 U/108 cells
and 0.5±0.6 U/107 cells, respectively). The PA-inhibitor activity
of platelets or leukocytes isolated from blood samples collected
3 and 5 h after injection of LPS was not different from that
of cells obtained from animals injected with saline (not shown).
In addition, no increase in inhibitor activity was observed in
plasma samples prepared from whole rabbit blood incubated
for different time intervals (up to 6 h) with endotoxin (10 qg/
ml blood) in vitro.
The following experiments were carried out to establish
whether the PA-inhibitor induced by endotoxin neutralized
the endogenous plasminogen activator released in vivo. Animals
were first injected with endotoxin (10 Mg/kg) or saline, and 3
h later, with AVP (10 Mug/kg). Blood samples were taken before
and 2, 5, 10, and 20 min after injection ofAVP and immediately
processed for plasminogen activator assay. The results are
shown in Fig. 2. In control animals, AVP induced a clear
increase of the euglobulin fibrinolytic activity. Preinjection of
endotoxin completely abolished the AVP-induced fibrinolytic
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To further document that inhibition of plasminogen acti-
vator occurred in vivo, endotoxin treated animals were injected
with 1,500 IU of human t-PA/kg body wt and blood samples
were taken at intervals on D-Ile-Pro-Arg-CH2Cl (2 X l0-4 M
final concentration). Gel filtration analysis of plasma samples
obtained from untreated animals 30 s after injection of activator
showed that most of the t-PA eluted in the albumin region
(Fig. 3 A). On the contrary, in plasma from animals with high
circulating levels of PA-inhibitor, virtually all of the t-PA
related antigen eluted with an apparent molecular weight of
100,000 (Fig. 3 B). A similar change in the elution profile was
observed when human t-PA was added to PA-inhibitor-rich
blood in vitro followed by addition of D-Ile-Pro-Arg-CH2Cl
after 2 min of incubation, but not when the synthetic inhibitor
was added before t-PA. This indicates that complex formation
between t-PA and PA-inhibitor in rabbit blood, after injection
of human t-PA, does not occur in vitro after collection of the
sample.
The disappearance of fibrinolytic activity in control rabbits
injected with human t-PA (1,500 IU/kg body wt) was consistent
with a half-life of -2 min. On the contrary, in endotoxin
treated animals, no activity (<0.1 U/ml) was detected 30 s
after t-PA injection, suggesting a half-life of a few seconds (not
shown).
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Figure 2. Fibrinolytic response to AVP (10 ,Ag/kg) in rabbits treated
with E. coli LPS (10 ug/kg) (n) or saline (-). AVP was given 3 h after
injection of LPS or saline. Data are the mean±SD of three experi-
ments.
Injection of 1,000 IU ofhuman t-PA/kg body wt in rabbits
2 h after injection of endotoxin resulted in a decrease of PA-
inhibitor activity in plasma from 26.3±6.4 to 5.5±1.4 U/ml.
This was followed by a progressive increase of PA-inhibitor
activity to 28.8±6.7 U/ml (n = 2) after 60 min (Fig. 4).
Donor-receiver transfusion experiments were carried out
to estimate the turnover rate of PA-inhibitor in rabbits (Fig.
5). Intravenous injection of plasma (20 ml) derived from
endotoxin treated animals (inhibitor-rich plasma) resulted in
a three- to fivefold increase of the circulating levels of PA-
inhibitor activity in the receiver animals (from 3.0±0.5 to
10.7±1.9 U/ml). This activity decayed with a half-life of about
7 min. No change in PA-inhibitor activity was observed in
animals injected with plasma from untreated rabbits, or with
plasma from endotoxin treated donor rabbits, which was
previously adsorbed with t-PA-Sepharose.
In vitro experiments with HEC. Conditioned medium
derived from cultured HEC incubated for 12-14 h in the
presence of endotoxin (10 ,ug/ml) had higher PA-inhibitor
activity than that from unstimulated cells (two- to sevenfold
increase) (Fig. 6). PA-inhibitor activity was detected also in
Triton extracts of endotoxin stimulated HEC (3.6±0.9 U/ml,
n = 4), but was virtually absent in extracts of control cells
(0.2±0.4 U/ml, n = 3). No PA-inhibitor activity was observed
in endotoxin containing culture medium incubated in cell-free
wells. Cell fractionation into membrane and soluble fraction
revealed that PA-inhibitor activity was confined to the latter
fraction. Unstimulated confluent cells derived from different
umbilical cords showed a different base-line rate of generation
of PA-inhibitor activity, while cells deriving from the same
cord generated comparable amounts of inhibitor activity. The
endotoxin-induced response (percent increase) was generally
more pronounced in HEC exhibiting low levels of inhibitor
activity.
Increased accumulation of PA-inhibitor activity in condi-
tioned medium of HEC cultures was already visible 4 h after
stimulation with endotoxin and was detectable at an endotoxin
concentration of 0.01 Ag/ml medium (Fig. 7).
A markedly reduced response or no response to endotoxin
was observed when confluent cells were stimulated in the
absence of human serum. Heat inactivated serum (30 min at
560C), but not human albumin (5 mg/ml), supported the
endotoxin-induced PA-inhibitor response.
PA-inhibitor activity in plasma ofpatients with septicemia.
As shown in Fig. 8, the plasma PA-inhibitor activity in five
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patients with septicemia was significantly higher than that
observed in a group of 50 control subjects tested simultaneously.
Gel filtration analysis of the patient plasma with highest PA-
inhibitor activity (41 U/ml) revealed that inhibition of t-PA
was associated with a change in the molecular weight, which
was similar to that observed in inhibitor rich rabbit plasma.
Adsorption of patient plasmas with t-PA-Sepharose resulted in
complete disappearance of PA-inhibitor activity.
UK inhibitor activity induced by endotoxin. A very strong
correlation (r = 0.98) was found between t-PA inhibitor activity
and UK inhibitor activity in patients' plasma, rabbit plasma,
and in conditioned culture medium of HEC (not shown). The
E 30 -
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Figure 4. Appearance of PA-inhibitor activity in the plasma of endo-
toxin treated rabbits. Animals were injected with E. coli (10 sg/kg
body wt) and 2 h later with human t-PA (1,000 IU/kg body wt). PA-
inhibitor activity in plasma was then measured at the indicated
intervals. Two separate experiments are shown.
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Figure 3. Elution pattern on Ultrogel AcA
f* ! ~~~~~~44of plasma samples from untreated rab-
bits (A) and endotoxin treated rabbits (B)
30 s after injection of human t-PA (1,500
IU/kg). E. coli LPS (10 pg/kg) or saline
i was injected 3 h before injection of t-PA.
Blood samples were anticoagulated with
trisodium citrate plus D-Ile-Pro-Arg-CH2CI
(2 X l0-4 M final concentration). The ar-
rows indicate the elution volume of human
IgGs, M, = 150 k; phosphorylase b, M,
'X - 98 k; and human albumin, M, = 66 k.Similar results were obtained in each of
20 25 30 three animals. ---, absorbance at
IMBER 280 nm; o -, t-PA antigen (ng/ml).
UK-inhibiting activity was completely removed by adsorption
of the samples with t-PA-Sepharose.
Discussion
The experiments reported in this paper demonstrate that
endotoxemia is associated with a marked and prolonged increase
of the circulating levels of PA-inhibitor activity. The dose of
endotoxin required for this response is very low (10 ng/kg
body wt), and far below that which produces overt intravascular
coagulation (200 gg/kg).
Inhibition of t-PA in the plasma of endotoxin treated
animals is due to the presence of a protease inhibitor as
indicated by the following observations. The addition of human
t-PA to inhibitor-rich rabbit plasma resulted in a change in
the molecular weight of the human activator with the formation
of a complex with an apparent molecular weight of 100,000.
All the PA-inhibitor activity was removed from plasma after
adsorption with t-PA Sepharose. Finally, interaction with the
plasma inhibitor was prevented when t-PA was treated with a
synthetic active site titrant, indicating that the active site of
the enzyme is required for the binding to the inhibitor.
Inhibition of injected human t-PA or of endogenous plas-
minogen activator(s) by the endotoxin-induced inhibitor also
occurred rapidly in vivo. First, no fibrinolytic response to
AVP, which is known to induce a marked t-PA release in man
(28), was detected in animals preinjected with endotoxin. This
might, however, be due to inhibition of plasminogen activator
release by endotoxin. Second, no free activator was found in
the circulation 30 s after injection of human t-PA in endotoxin
treated animals. The change in the gel filtration pattern of
human t-PA antigen paralleled the disappearance of t-PA
activity in the blood of rabbits with high levels of PA-inhibitor.
In untreated animals, the half-life of human t-PA was, in
agreement with previous results (29), -2 min. It has been
demonstrated that clearance of t-PA from the circulation is
mainly due to uptake by the liver; no interaction with any of
the plasma protease inhibitors could be documented (29).
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Figure 5. Turnover rate of PA-inhibitor
activity in rabbits. (A) Disappearance of
circulating PA-inhibitor activity in rab-
bits injected with inhibitor-rich plasma
(20 ml, 36-53 U/ml). Results are the
mean±SD of three experiments. (B)
PA-inhibitor response in rabbits in-
jected with normal plasma (A) or PA-
*L IL*a inhibitor rich plasma adsorbed with t-
0 5 10 15 20 PA-Sepharose (.). Results are the mean
and range of two experiments.
However, in endotoxin treated rabbits, human t-PA activity
disappeared within a few seconds, due to neutralization by the
circulating inhibitor.
Increased levels of PA-inhibitor activity in endotoxin treated
rabbits were maintained for about 5 h. This prolonged response
to endotoxin resulted from continuous release of PA-inhibitor
into the circulation as indicated by its short half-life (about
- 7 min) and by the progressive rise in the levels of the
inhibitor in plasma after its depletion by injection of hu-
man t-PA.
The origin of the PA-inhibitor found in the circulating
blood of endotoxin treated animals is unclear. Blood cells do
not seem to contribute to this endotoxin-induced response as
suggested by the fact that no increase in the cell-associated
PA-inhibitor activity was found in leukocytes and platelets
isolated from blood obtained from endotoxin injected rabbits.
Furthermore, the plasma levels of PA-inhibitor were unchanged
20r
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Figure 6. PA-inhibitor activity in the culture medium of HEC incu-
bated for 12-14 h with E. coli LPS (10 gg/ml) (open bars) or saline
(stippled bars). Results represent mean±SD of experiments carried
out on three separate cell cultures derived from the same umbilical
cord. Four series of experiments (A to D) are shown.
after in vitro stimulation of rabbit blood with endotoxin. The
contribution of the endothelium in the generation of PA-
inhibitor activity in blood is suggested by the experiments
carried out with cultured human endothelial cells. These
experiments indeed showed that addition of endotoxin to
endothelial cells resulted in an increased accumulation of PA-
inhibitor activity in the surrounding medium. The available
data, however, do not allow us to conclude that the inhibitor
found in endothelial cells (8-12) is the same as that found in
plasma (13-15).
Stimulation of endothelial cells by endotoxin is mediated
by a serum factor that is heat stable and thus does not require
activation of the complement system. Cell damage does not
seem to be a prerequisite for the occurrence of the endotoxin-
induced PA-inhibitor response. No endothelial cell damage
was observed after exposure to endotoxin in vitro (5). Moreover,
the minimum dose of endotoxin capable of inducing a marked
inhibitor response in vivo (10 ng/kg body wt) is at least two
orders of magnitude lower than the dose shown to produce
vascular lesions in rabbits (4, 30).
All of five patients with septicemia had circulating levels
of PA-inhibitor above 4 U/ml, whereas <1% of 700 plasma
samples from normal subjects had PA-inhibitor activity above
this value (unpublished). This suggests that the PA-inhibitor
response to endotoxin is a relevant physiopathological phe-
nomenon in man.
The strong correlation found under all conditions between
inhibition of t-PA and inhibition of UK, and the fact that all
the UK inhibitor activity is removed by adsorption with t-PA-
Sepharose, indicate that this fast inhibitor interacts with both
plasminogen activators.
The possible role of PA-inhibitor in the pathogenesis of
endotoxin-induced DIC is inferred from different observations.
First, Hofmann and co-workers (31) showed that infusion of
low doses of soluble Des-A fibrin, the product of the proteolytic
removal of fibrinopeptide A from fibrinogen by thrombin,
resulted in generation of renal glomerular microclots in en-
dotoxin treated rabbits, but not in untreated animals. Microclot
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Figure 7. (A) Appearance of PA-in-
hibitor activity in conditioned me-
dium of cultured HEC stimulated
with E. coli LPS (10 gg/ml) (n) or
saline (.). Aliquots of culture me-
dium (80 Ml) were taken at the indi-
cated intervals. Results are the
mean±SD of six experiments car-
ried out on cell cultures derived
from two different umbilical cords.
(B) PA-inhibitor activity in the cul-
ture medium of HEC stimulated for
12 h with different concentrations of
E. coli LPS. Each value represents
mean and range of two experiments
carried out on cell cultures derived
from two different umbilical cords.
formation seemed to be caused by defective fibrinolysis. Indeed,
glomerular microthrombi were also observed after Des-A fibrin
infusion in animals treated with aprotinin, a fibrinolytic inhib-
itor. Secondly, pregnancy is known to predispose to the
Sanarelli-Shwartzman reaction (32). Margaretten and colleagues
(33) observed that prolonged infusion of thrombin resulted in
renal cortical necrosis in a large proportion of pregnant rats,
whereas there were no lesions in nonpregnant animals. Throm-
bin infusion also caused renal cortical necrosis in nonpregnant
40r
animals that had received an infusion of epsilon-amino caproic
acid, an inhibitor of plasminogen activation. This again suggests
that during pregnancy, the reduction of the fibrinolytic capacity
may be one of the pathogenetic mechanisms leading to en-
hanced sensitivity to thrombogenic stimuli. Finally, recent
reports have shown a significant increase of the level of PA-
inhibitor activity in plasma during pregnancy (34, 35).
In conclusion, our results suggest that the generation of a
fast-acting PA-inhibitor activity in the circulation may contrib-
ute to DIC associated with endotoxemia. The findings that the
appearance of PA-inhibitor is very sensitive to certain stimuli
and that it efficiently modulates the activity of the fibrinolytic
system in vivo underscore. its potential pathophysiological role
in hemostasis.
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